Bli medlem
Bli medlem

Du är här


Curetis: Curetis to host conference call and webcast on GEAR acquisition

Curetis / Curetis to host conference call and webcast on GEAR acquisition.
Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely
responsible for the content of this announcement.
Amsterdam, the Netherlands and Holzgerlingen, Germany, September 07, 2016
-- Curetis N.V. (the "Company
" and, together with Curetis GmbH, "Curetis
"), a developer of next-level molecular diagnostic solutions, today announced
that it will host a public conference call and webcast on September 8, 2016,
at 03:00 pm CET / 09:00 am EST to present its asset acquisition agreement
with Siemens Technology Accelerator GmbH (STA) announced earlier today. Under
the terms of the agreement, Curetis has acquired sole commercial rights from
STA to the GEAR GEnetic Antibiotic Resistance and Susceptibility platform and
database with all its content, numerous GEAR-related patents and patent
applications, as well as all corresponding know-how.

The conference call will be supplemented by a presentation, which can be
accessed during the call
at The live
webcast and a replay will be available
at' passcode

To access the call, please dial the following numbers using the passcode

Germany: +49 692 222 290 43

UK: +44 203 009 2452

US: +1 855 402 7766

For further international dial-in numbers, please open the following
link: Access Numbers_


CAUTION - Investigational device. Limited by Federal (or United States) law to
investigational use. The information contained in this communication does not
constitute nor imply an offer to sell or transfer any product, and no product
based on the Curetis Unyvero technology is currently available for sale in
the United States of America or Canada. The analytical and clinical
performance characteristics of any Curetis Unyvero product which may be sold
at some future point in time in the U.S. have not yet been established.


About Curetis

Founded in 2007, Curetis is a molecular diagnostics company which focuses on
the development and commercialization of reliable, fast and cost-effective
products for diagnosing severe infectious diseases. The diagnostic solutions
of Curetis enable rapid multi-parameter pathogen and antibiotic resistance
marker detection in only a few hours, a process that today can take up to
days or even weeks with other techniques.

To date, Curetis has raised EUR 44.3 million in an IPO on Euronext Amsterdam
and Euronext Brussels and private equity funds of over EUR 63.5 million. The
company is based in Holzgerlingen near Stuttgart, Germany. Curetis has signed
collaboration agreements with Heraeus Medical and Cempra Inc. as well as
several international distribution agreements covering many countries across
Europe, the Middle East and Asia.

For further information, please visit

Legal Disclaimer

This document constitutes neither an offer to buy nor to subscribe securities
and neither this document nor any part of it should form the basis of any
investment decision in Curetis.

The information contained in this press release has been carefully prepared.
However, Curetis bears and assumes no liability of whatever kind for the
correctness and completeness of the information provided herein. Curetis does
not assume an obligation of whatever kind to update or correct information
contained in this press release whether as a result of new information,
future events or for other reasons.

This press release includes statements that are, or may be deemed to be,
"forward-looking statements". These forward-looking statements can be
identified by the use of forward-looking terminology, including the terms
"believes", "estimates", "anticipates", "expects", "intends", "may", "will",
or "should", and include statements Curetis makes concerning the intended
results of its strategy. By their nature, forward-looking statements involve
risks and uncertainties and readers are cautioned that any such
forward-looking statements are not guarantees of future performance. Curetis'
actual results may differ materially from those predicted by the
forward-looking statements. Curetis undertakes no obligation to publicly
update or revise forward-looking statements, except as may be required by

Contact details

Max-Eyth-Str. 42
71088 Holzgerlingen, Germany
Tel. +49 7031 49195-10

International Media&Investor Inquiries

Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68

U.S. Media&Investor Inquiries

The Ruth Group
Lee Roth
Tel. +1 646 536 7012

20160907_Curetis_PR_GEAR ConfCall EN _FINAL
Curetis Logo


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Curetis via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.